Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics, Inc. - Common Stock
(NQ:
PTGX
)
88.90
+2.31 (+2.67%)
Streaming Delayed Price
Updated: 11:31 AM EST, Feb 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Protagonist Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
↗
February 16, 2026
This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance.
Via
The Motley Fool
Topics
Regulatory Compliance
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
↗
February 01, 2026
The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple.
Via
The Motley Fool
Topics
Regulatory Compliance
"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
January 15, 2026
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In
↗
October 14, 2025
Via
Stocktwits
9 Analysts Assess Protagonist Therapeutics: What You Need To Know
↗
June 03, 2025
Via
Benzinga
Protagonist (PTGX) Earnings Call Transcript
↗
November 27, 2025
Protagonist (PTGX) Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
What 7 Analyst Ratings Have To Say About Protagonist Therapeutics
↗
October 28, 2025
Via
Benzinga
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million
↗
October 23, 2025
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million
Via
The Motley Fool
Topics
Energy
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million
↗
October 23, 2025
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million
Via
The Motley Fool
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million
↗
October 21, 2025
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million
Via
The Motley Fool
Topics
Regulatory Compliance
2 Top Dividend Kings Every Income Investor Should Own
↗
October 20, 2025
These companies pay durable and steadily rising dividends.
Via
The Motley Fool
Topics
Bonds
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
↗
October 18, 2025
Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.
Via
MarketBeat
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook
↗
October 14, 2025
Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes.
Via
Benzinga
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print
↗
October 14, 2025
Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.
Via
Stocktwits
Topics
Government
World Trade
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
↗
October 13, 2025
Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.
Via
Benzinga
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy
↗
October 13, 2025
FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit.
Via
Benzinga
Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears
↗
October 13, 2025
U.S. markets were rattled on Friday after President Trump reignited trade tensions with China, triggering the sharpest sell-off since April. Tech and AI stocks led the decline, while gold and...
Via
Chartmill
Topics
Artificial Intelligence
Government
World Trade
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
↗
October 10, 2025
The company could soon be swallowed by a very large peer -- which also happens to be a business partner.
Via
The Motley Fool
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
October 10, 2025
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
↗
October 10, 2025
Via
Benzinga
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
↗
October 10, 2025
Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio.
Via
Benzinga
Which stocks are experiencing notable movement on Friday?
↗
October 10, 2025
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
5 Analysts Assess Protagonist Therapeutics: What You Need To Know
↗
October 08, 2025
Via
Benzinga
Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews
↗
September 17, 2025
Via
Benzinga
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials
↗
September 17, 2025
Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.
Via
Benzinga
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
September 17, 2025
Via
Benzinga
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
↗
September 12, 2025
Via
Benzinga
What 4 Analyst Ratings Have To Say About Protagonist Therapeutics
↗
August 07, 2025
Via
Benzinga
Protagonist (PTGX) Q2 Revenue Falls 26%
↗
August 07, 2025
Via
The Motley Fool
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
↗
June 30, 2025
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
